The finding carries immediate clinical implications. Screening recommendations for people with Crohn’s disease and ulcerative colitis, the two principal forms of IBD, currently instruct clinicians to look primarily at whether a single close relative developed colorectal cancer early in life. If a patient answers no, family history is often dismissed as a risk factor, and surveillance intervals are set accordingly. But the new data indicate that this binary approach may miss the forest for the trees. What appears to matter most is not the age at which one relative was diagnosed, but the sheer accumulation of cancer cases across a patient’s closest family members. In other words, a patient with two siblings or a parent and a sibling who both had colorectal cancer may be at far greater risk than a patient with one relative who was diagnosed young.

“Current international guidelines for IBD patients emphasise whether a first-degree relative has developed colorectal cancer before the age of 50. However, our study shows that the number of cancer cases in the family may be a more important risk marker,” says Åsa Everhov, senior consultant in surgery at Södersjukhuset and associate professor at the Department of Medicine, Solna, Karolinska Institutet, who led the study.

The research drew on the extraordinary depth of Sweden’s national health registries, a resource that allows scientists to follow entire populations across decades. The team identified 124,387 people diagnosed with IBD in Sweden between 1996 and 2023 and compared them with more than 1.2 million matched individuals from the general population. Participants were followed for a median of eleven years, during which 1,882 people with IBD developed colorectal cancer. The registry infrastructure behind the study is formidable: the researchers combined data from the Patient Register, the Cancer Register, the Cause of Death Register and the Multigenerational Register—a database that links Swedes across generations through their personal identity numbers—alongside the national ESPRESSO cohort, a purpose-built research platform for gastroenterology. This multigenerational linkage is what makes such a granular analysis of family cancer history possible; in most countries, reliably cataloguing the cancer diagnoses of every parent, sibling and child of more than a hundred thousand patients would be an impossible task.

The scale of the comparison group matters as much as the size of the patient cohort. By matching IBD patients against 1.2 million cancer-free comparators from the same population, the researchers were able to disentangle two risk factors that usually travel together: the presence of IBD and the presence of inherited susceptibility. One of the study’s most striking results emerged from precisely this comparison. People who had at least one first-degree relative with colorectal cancer showed roughly the same absolute risk of developing the disease whether or not they had IBD. Family history, in other words, did not appear to multiply the risk conferred by IBD so much as to sit alongside it as an independent and potent signal.

That observation challenges an intuitive assumption. Clinicians might expect that inherited genetic susceptibility and chronic intestinal inflammation would interact, with each amplifying the other to produce a risk greater than the sum of its parts. The data instead suggest a more additive picture, and they raise a provocative question about how risk should be categorised. If an IBD patient with a strong family history carries an absolute cancer risk similar to that of a person without IBD but with the same family history, then the intensity of surveillance might in some cases be driven more by the family tree than by the underlying inflammatory condition.

“The highest risk was observed in people with IBD who had two or more first-degree relatives with colorectal cancer,” the authors report, and the magnitude of that elevation—approximately 2.6-fold compared with family-history-negative IBD patients—places a substantial minority of patients into a risk category that current algorithms may fail to flag. “By comparison, the risk was only just under 50 per cent higher among IBD patients with a first-degree relative who had developed colorectal cancer before the age of 50. This raises the question of whether the number of affected relatives should carry greater weight when assessing cancer risk,” says Ola Olén, senior consultant in paediatric gastroenterology at Sachs’ Children and Youth Hospital and adjunct professor at the Department of Medicine, Solna, Karolinska Institutet, who co-led the work.

The biological rationale for counting relatives rather than fixating on age of onset is not hard to reconstruct. Colorectal cancer clusters in families for reasons that range from rare, high-penetrance inherited syndromes—such as Lynch syndrome and familial adenomatous polyposis—to far more common combinations of shared genes, shared environments and shared lifestyle exposures. Each additional affected first-degree relative increases the statistical likelihood that a shared, heritable susceptibility is at work. A single early-onset case is a meaningful warning sign, but two or more cases among parents, siblings or children represent a stronger signal of an underlying familial predisposition, and it is this cumulative burden that the Swedish data show to be the sharper predictor for patients already carrying the inflammatory burden of IBD.

For patients, the practical takeaway is straightforward: when a gastroenterologist takes a family history, the detail that matters may be the count of affected relatives, not just their ages at diagnosis. Patients with IBD should know and report the colorectal cancer histories of their parents, siblings and children as completely as possible. For clinicians and guideline developers, the study adds to a growing body of evidence that risk stratification in IBD surveillance—currently built largely around disease duration, extent of colonic involvement and the presence of inflammation on histology—should be refined to incorporate the full architecture of a patient’s family cancer history. Colonoscopy surveillance intervals, the study suggests, might one day be shortened not only for patients whose single relative was diagnosed young, but for those whose families carry multiple cases regardless of age at onset.

The work also demonstrates the enduring value of population-scale register research. Because the Swedish registries capture diagnoses, deaths and kinship links for essentially the entire national population over nearly three decades, the study avoids many of the pitfalls that plague smaller, hospital-based investigations: recall bias, selective participation and under-ascertainment of family history. Family history reported by patients in clinic is notoriously incomplete; registry-derived history is not. The result is one of the largest and most complete assessments ever conducted of how familial colorectal cancer shapes risk in the IBD population, and it arrives at a moment when health systems worldwide are searching for ways to target screening resources more precisely.

The study was funded by the Swedish Research Council, the Swedish Cancer Society, Vinnova, ALF funding from Region Stockholm, Karolinska Institutet and ERA PerMed, among others. Several of the authors report research collaborations, research grants or other assignments with pharmaceutical companies, as disclosed in the scientific article.

Whether the finding will reshape international guidelines remains to be seen, but the direction of the evidence is clear. For the millions of people worldwide living with Crohn’s disease and ulcerative colitis, the number of loved ones who have faced colorectal cancer may be the single most informative question their doctors are not yet asking.